DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/97b318/partnering_in_the) has announced the addition of the "Partnering in the Global Generics Industry 2008: A Guide to Companies" report to their offering.

Partnering is increasingly the choice for securing market share and business growth...

... Teva’s recent acquisition of Barr Pharmaceuticals may be the latest headline grabbing deal, but industry and commerce alike must have a complete understanding of the medium-sized generic drug manufacturers. The operating environment is changing rapidly as the industry matures and growth focuses on new market opportunities.

Consolidation continues to affect the market, with fewer big players dominating. Acquisition is still a favoured route to fast market access but strategic partnering is on the rise. In such a market you need to know...

But…

- Who are the medium-sized companies of note?

- How well do they perform?

- What drugs do they produce?

- Where are they located?

This report will tell you!

Executive Summary:

Identify merger, acquisition and partner candidates in the rapidly changing global generics market. Consolidation runs throughout the generic industry. Here’s just a taste of the acquisitions and controlling investments in 2007/08:

- Target

- Strides

- TAD

- AxiCorp GmbH

- Medicamenta

- Kyowa Pharmaceutical

- Alkan Pharma

- Hisyn Pharmaceutical

- Buyer

- Genepharm

- Aurobindo

- Biocon

- Glenmark

- Lupin Laboratories

- Hikma

- Hovione

Teva and Sandoz may be fighting it out for the top spot but the medium-sized corporate landscape is changing just as vigorously.

Strategic partnering:

In addition to outright purchase, strategic partnering or the acquisition of specific drug assets is on the rise as companies seek to bring lower costs and focus to their portfolios. With business cycles growing shorter and shorter, market entry is quicker and more reliable through acquisition and partnering.

Drivers for change:

In addition to ongoing expansion, there are other drivers which are causing the generic companies to consider the future:

- The number of new generic drug opportunities is reducing in line with the decline in NDAs over recent years. Furthermore, the branded industry is far more aware of the potential to protect revenues by issuing early branded generics, new formulations or combination products.

- The increasing introduction of biotech based products will present regulatory and production hurdles to generic manufacturers in the future.

Identify new business opportunities and assess risk:

For everyone needing to evaluate the generic industry’s competitive landscape, this new, thoroughly researched 406-page report Partnering in the Global Generics Industry 2008:

- A guide to companies (published July 2008) is an essential business reference.

- Unbeatable coverage

- For each company where available or appropriate

- Background

A Summary of the Company’s Foundation and Main Business Interests

- Product Range

Details of Andas Approved or Products Represented

- Financial

Financial Performance or Funding Data

- Strategic Alliances

Details of Significant Marketing and Supply Agreements

- Contact Information

Use this report to:

- Identify commercial partners

- Understand the developing generic industry in key markets worldwide

- Profile the competitive environment in the increasingly important medium-sized company sector

- Seek out companies manufacturing/marketing similar product lines

- Assess the investment potential of these developing companies

- 163 companies from 40 countries evaluated

Some key topics (Follow link provided for the full list)

Introduction

Argentina

Osmotica Pharmaceutical

Products

Australia

Australian Pharmaceutical Industries

Financials

Major Developments

GenePharm Australasia

Products

Financials

Major Developments

Hamilton Laboratories

Products

Sigma Pharmaceuticals

Products

Financials

Major Developments

Bangladesh

Beximco Pharmaceuticals

Products

Financials

Major Developments

For a list of companies mentioned please follow the link provided and for more information visit http://www.researchandmarkets.com/research/97b318/partnering_in_the

Source: Espicom Business Intelligence Ltd

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716